Real-World Early Outcomes of Second-Line Axicabtagene Ciloleucel (Axi-Cel) Therapy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

被引：0

作者：

Lee, Dasom ^{[1
]}

Kambhampati, Swetha ^{[2
]}

Bobillo, Maria Silvina Odstrcil ^{[3
]}

Adedokun, Babatunde ^{[4
]}

Shadman, Mazyar ^{[5
,6
]}

Olson, Amanda L. ^{[7
]}

Herrera, Alex F. ^{[8
]}

Lee, Catherine J. ^{[5
,6
]}

Jacobson, Caron A. ^{[9
]}

Bye, Matthew ^{[10
]}

Hamadani, Mehdi ^{[10
]}

Kim, Soyoung ^{[11
]}

Dahiya, Saurabh ^{[12
]}

Hu, Zhen-Huan ^{[4
]}

Speth, Kelly ^{[4
]}

To, Christina ^{[4
]}

Mirjah, Debbie L. ^{[13
]}

Best, Timothy ^{[4
]}

Locke, Frederick L. ^{[14
]}

Ahmed, Nausheen ^{[15
]}

Tees, Michael T. ^{[16
]}

Pasquini, Marcelo C. ^{[17
]}

Ahmed, Sairah ^{[18
]}

机构：

[1] Stanford Univ, Div Hematol, Palo Alto, CA USA

[2] City Hope Natl Med Ctr, Yorba Linda, CA USA

[3] Univ Utah, Salt Lake City, UT USA

[4] Kite A Gilead Co, Santa Monica, CA USA

[5] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA USA

[6] Med Oncol Div, Seattle, WA USA

[7] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[8] City Hope Natl Med Ctr, Dept Hematol & Hematopoiet Cell Transplantat, Duarte, CA USA

[9] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA

[10] Med Coll Wisconsin, Ctr Int Blood & Marrow Transplant Res CIBMTR, Milwaukee, WI USA

[11] Med Coll Wisconsin, Ctr Int Blood & Marrow Transplant Registry CIBMTR, CIBMTR Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI USA

[12] Stanford Univ, Div Hematol, Stanford, CA USA

[13] Gilead Co, Santa Monica, CA USA

[14] H Lee Moffitt Canc Ctr & Res Inst, Blood & Marrow Transplant & Cellular Immunotherapy, Tampa, FL USA

[15] Univ Kansas, Div Hematol Malignancies & Cellular Therapeut, Med Ctr, Kansas City, KS USA

[16] Sarah Cannon transplant & Cellular Therapy Network, Nashville, TN USA

[17] Dana Farber Canc Inst, Boston, MA USA

[18] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma & Stem Cell Transplantat, Houston, TX USA

来源：

BLOOD | 2024年 / 144卷

关键词：

D O I：

10.1182/blood-2024-199139

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：527 / 528

页数：2

共 50 条

[31] Second-Line Axicabtagene Ciloleucel Improves OS in Early Relapsed or Refractory Large B-Cell Lymphoma
O'Brien, Susan
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2023, 21 (07) : 360 - 361
[32] Real-world early outcomes of axicabtagene ciloleucel for relapsed or refractory (R/R) follicular lymphoma (FL).
Jacobson, Caron Alyce
Hemmer, Michael T.
Hu, Zhen-Huan
Frank, Matthew Joshua
Popplewell, Leslie
Ahmed, Nausheen
Lin, Yi
Best, Timothy
Beygi, Sara
Miao, Harry H.
Fu, Christine
Sun, Fang
Xu, Hairong
Pasquini, Marcelo C.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[33] Preliminary results of earlier steroid use with axicabtagene ciloleucel (Axi-Cel) in patients with relapsed/refractory large B cell lymphoma
Topp, M. S.
van Meerten, T.
Wermke, M.
Lugtenburg, P. J.
Minnema, M. C.
Song, K. W.
Thieblemont, C.
Jiang, Y.
Plaks, V
Kerber, A.
Kersten, M. J.
ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 65 - 66
[34] Matching-Adjusted Indirect Comparison (MAIC) of Axicabtagene Ciloleucel (Axi-Cel) and Lisocabtagene Maraleucel (Liso-Cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) After Two or More Prior Lines of Therapy
Oluwole, Olalekan O.
Chen, Jenny M. H.
Chan, Keith
Patel, Anik R.
Jansen, Jeroen P.
Keeping, Sam
Bashir, Zahid
Zheng, Yan
Snider, Julia
Locke, Frederick L.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S388 - S388
[35] Outcomes of patients (pts) ≥ 65 years of age in ZUMA-1, a pivotal phase 1/2 study of axicabtagene ciloleucel (axi-cel) in refractory large B-cell lymphoma (LBCL).
Neelapu, Sattva Swarup
Jacobson, Caron A.
Oluwole, Olalekan O.
Munoz, Javier
Deol, Abhinav
Miklos, David Bernard
Bartlett, Nancy L.
Braunschweig, Ira
Jiang, Yizhou
Kim, Jenny J.
Zheng, Lianqing
Rossi, John M.
Locke, Frederick Lundry
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[36] Analysis of PET-CT Derived Radiomic Biomarkers with Efficacy, Safety, and Expansion of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed or Refractory Large B-Cell Lymphoma (LBCL)
Bharadwaj, Sushma
Lau, Eric
Hashmi, Ayesha
Hamilton, Mark P.
Jensen, Alexandria
Goyal, Anmol
Marar, Mallika
Lee, Caroline
Ananth, Snegha
Sahaf, Bita
Mallampet, Jayasindhu
Ehlinger, Zachary
Syal, Shriya
Patil, Sunita
Guo, Henry
Smith, Melody
Weng, Wen-Kai
Frank, Matthew J.
Binkley, Michael S.
Miklos, David B.
Dahiya, Saurabh
BLOOD, 2023, 142
[37] INDIRECT TREATMENT COMPARISON OF AXICABTAGENE CILOLEUCEL (AXI-CEL) VERSUS TISAGENLECLEUCEL (TISA-CEL) IN RELAPSED/REFRACTORY LARGE B CELL LYMPHOMA (RR-LBCL)
Oluwole, O.
Jansen, J. P.
Lin, V
Chan, K.
Navale, L.
Kim, J. J.
Locke, F. L.
VALUE IN HEALTH, 2019, 22 : S522 - S522
[38] Resource Utilization and Factors Prolonging Hospitalization for Patients with Refractory and Relapsed B-Cell Lymphoma Receiving Axicabtagene Ciloleucel (Axi-cel)
Mian, Agrima
Wei, Wei
Hill, Brian T.
Hamilton, Betty K.
Pohlman, Brad
Jagadeesh, Deepa
Anwer, Faiz
Kalaycio, Matt E.
Dean, Robert M.
Sobecks, Ronald M.
Majhail, Navneet S.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (03) : S44 - S45
[39] Retreatment of Patients With Refractory Large B Cell Lymphoma With Axicabtagene Ciloleucel (Axi-Cel) in ZUMA-1
Locke, Frederick
Bartlett, Nancy
Jacobson, Caron
Oluwole, Olalekan
Munoz, Javier
Lekakis, Lazaros
Topp, Max
Avivi, Irit
Kim, Jenny
Chu, Rong
Zheng, Lianqing
Rossi, John
Bot, Adrian
Neelapu, Sattva
AMERICAN JOURNAL OF HEMATOLOGY, 2020, 95 : S21 - S22
[40] A Comparison of 2-Year Outcomes in ZUMA-1 (Axicabtagene Ciloleucel [Axi-Cel]) and SCHOLAR-1 in Patients (Pts) with Refractory Large B Cell Lymphoma (LBCL)
Neelapu, Sattva S.
Locke, Frederick L.
Bartlett, Nancy L.
Lekakis, Lazaros J.
Reagan, Patrick M.
Miklos, David B.
Jacobson, Caron A.
Braunschweig, Ira
Oluwole, Olalekan O.
Siddiqi, Tanya
Lin, Yi
Crump, Michael
Kuruvilla, John
Van Den Neste, Eric
Farooq, Umar
Navale, Lynn
DePuy, Venita
Kim, Jenny J.
Gisselbrecht, Christian
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (03) : S232 - S232

← 1 2 3 4 5 →